MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.blre.2025.101317

Медицинская библиотека · Blood reviews · 2025

Novel therapies for acute myeloid leukemia. Does age still matter?

Krayem Baher, Frisch Avraham, Horowitz Netanel

СтатьяОбзорПеревод пока не подготовлен

Аннотация

The prognosis of patients with AML varies significantly with age, driven by biological heterogeneity and age-associated factors such as comorbidities, functional status, and hospitalization burden. Many novel therapies have been approved in recent years; however, pivotal trials often include patients within a restricted age range, limiting the extrapolation of their findings across the broader AML population. For example, the FLT3 inhibitor midostaurin was added to chemotherapy for patients aged 18-60 years, while the BCL-2 inhibitor venetoclax was combined with azacitidine in patients aged 75 years and older, leaving important knowledge gaps regarding their efficacy and safety in other age groups. Moreover, for several novel therapies, particularly in populations outside the original trial age range, supporting evidence is derived primarily from single-arm studies or real-world experience rather than randomized controlled trials, further complicating clinical decision-making. This review explores the efficacy and safety of widely used traditional and novel therapies for AML, with particular focus on the impact of age on these different therapeutic regimens.

Для цитирования: Krayem Baher, Frisch Avraham, Horowitz Netanel. Novel therapies for acute myeloid leukemia. Does age still matter?. Blood reviews. 2025. DOI: 10.1016/j.blre.2025.101317.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.